Neutralisi

Neutralising antibody responses to mpox wane 2 years after infection or vaccination

Neutralising antibodies against monkeypox virus waned significantly over 2 years following either natural infection or Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) vaccination, according to a retrospective study that tracked immunological responses in 90 men. The study -- published in The Journal of Infectious Diseases -- found that only 24.44% of participants retained positive neutralising antibody (NAb) titres at the 90% cytopathic effect inhibitory concentration (IC90), whilst 58.8% showed positive titres at 50% cytopathic effect inhibitory concentration (IC50).  According to Nic...

One night of sleep may reveal years of future disease risk

Researchers at Stanford University have developed a multimodal sleep foundation model that uses polysomnography (PSG) recordings to predict a person's risk of developing future health conditions with high accuracy, according to a study published in N...

Nirsevimab or maternal RSVpreF vaccination: Which offers better RSV protection for infants?

Passive infant immunisation with nirsevimab was associated with a significantly lower risk of respiratory syncytial virus (RSV)-related hospitalisation and severe outcomes during early infancy compared with maternal vaccination using the RSV prefusio...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Highligths
3:19

Highligths of SABCS 2025

Presenter: Virginia G. Kaklamani
Oncology : Breast Cancer
SABCS 2025
Lymphoma a
6:18

Lymphoma and CLL highlights of the ASH 2025

Presenter: Catherine Diefenbach
Hematology
ASH 2025
Available
7:02

Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

Presenter: Matthew S. Davids
Hematology
ASH 2025
Novelties
4:28

Novelties in Acute Myeloid Leukemia at ASH2025

Presenter: Mark Levis
Hematology
ASH 2025
What's new
3:09

What's new in myeloma?

Presenter: Enrique Ocio
Hematology
ASH 2025
Azacitidin...
6:18

Azacitidine–Venetoclax Combination Outperforms Standard Care in Acute Myeloid Leukemia Patients Eligible for Intensive Chemotherapy

Presenter: Amir Fathi
Hematology
ASH 2025
Symptom-ba
2:56

Symptom-based progression-free survival as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial

Presenter: Jennifer R. Brown
Hematology
ASH 2025
Validation
6:06

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Presenter: Jesse Tettero
Hematology
ASH 2025
Primary ef
4:38

Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL

Presenter: Anand Patel
Hematology
ASH 2025
Non-covale
6:26

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

Presenter: Jennifer A. Woyach
Hematology
ASH 2025
Quadruplet
12:01

Quadruplet Therapy in Multiple Myeloma

Presenter: Rahul Banerjee
Hematology
ASH 2025
Novelties
6:08

Novelties in Diffuse Large B-cell Lymphoma at ASH2025

Presenter: Joshua Brody
Hematology
ASH 2025
Breakthrou
11:20

Breakthrough in the treatement of Multiple Myeloma

Presenter: Xavier Leleu
Hematology
ASH 2025
Diagnosis
13:17

Diagnosis and Management of Cold Agglutinin Disease

Presenter: Sigbjorn Berentsen
Hematology
ASH 2025
Multiple M
9:11

Multiple Myeloma Highlights from ASH 2025

Presenter: Paul G. Richardson
Hematology
ASH 2025
COBRA tria
16:05

COBRA trial and other novelties in multiple myeloma at ASH 2025

Presenter: Andrzej Jakubowiak
Hematology
ASH 2025
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology